Caris MI Clarity
Next-Generation Prognostic Tool that Leverages Multimodal AI Technology and Computational Pathology for Early-Stage HR+, HER2-, Node-Negative Breast Cancer Patients
Early Access Opportunity
During this early access period, which runs through mid-August, participating providers can access the tests and will be asked to complete a brief feedback survey. This is a unique chance to be among the first to experience and shape the future of breast cancer prognostics with Caris.
Get Early Access
What it is:
Caris MI Clarity™ is a multimodal, multitask deep learning AI model for breast cancer recurrence risk. No genomic sequencing is required.
Why it matters:
Caris MI Clarity predicts both early and late breast cancer recurrence risks at diagnosis, helping clinicians make more informed decisions with greater confidence across the full treatment journey.
WHY MI CLARITY?
A More Complete View of Breast Cancer Recurrence Risk
Treatment decisions in early-stage breast cancer are often made without full visibility into long-term recurrence risk. But what if both windows of risk — early and late — were clear before the first decision?
Caris has a new approach to prognostic assessment in early-stage breast cancer. Caris MI Clarity provides clarity at diagnosis and confidence for the path forward.
Caris MI Clarity is a multimodal, multitask deep learning AI model for breast cancer recurrence risk. No genomic sequencing required.
Analyzes digitized H&E whole slide images combined with clinical inputs to stratify patients into low- and high-risk categories for both early (Years 0-5) and late (Years 5-15) distant recurrence.
Supported by robust clinical data from the TAILORx1 and NSABP B-422 trials, Caris MI Clarity offers more precise risk stratifications — with a turnaround time of just 1-3 days.
Next-Generation Prognostic Tool
Why Caris MI Clarity Stands Apart
See the Full Horizon. Plan
the Journey Ahead.
- Reports two independent distant recurrence risks: early window (Years 0-5) and late window (Years 5-15)
- One test at diagnosis
Thoroughly Validated.
Expanding to Serve More
Patients.
- Trained and validated on data from TAILORx and NSABP B-42, landmark trials behind today’s standard of care
- Actively expanding evidence base to cover more patients
Faster Results, Lower Cost, Broader Access.
1-3 days turnaround from qualified sample receipt vs. up to 14 days for standard genomic sequencing tests
Publication Highlight
Multimodal Artificial Intelligence (AI) Models Integrating Image Clinical and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx
1 Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Jr., Dees, E. C., Goetz, M. P., Olson, J. A., Jr., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P. M., . . . Sledge, G. W., Jr. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med, 379(2), 111-121. https://doi.org/10.1056/NEJMoa1804710
2 Mamounas, E. P., Bandos, H., Rastogi, P., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Jr., Fehrenbacher, L., Chia, S. K., Brufsky, A. M., Walshe, J. M., Soori, G. S., Dakhil, S. R., Wade, J. L., 3rd, McCarron, E. C., Swain, S. M., & Wolmark, N. (2023). Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst, 115(11), 1302-1309. https://doi.org/10.1093/jnci/djad078
Caris MI Clarity
